Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.

Oncoimmunology
Archana ThakurLawrence G Lum

Abstract

In this study, we investigated the ability of bispecific antibody armed activated T cells to target drug resistant pancreatic cancer cells and whether or not "priming" these resistant cancer cells with bispecific antibody armed activated T cells could enhance subsequent responsiveness to chemotherapeutic drugs. Chemotherapeutic responses for pancreatic cancer are either limited or the tumors develop resistance to chemotherapy regimens. The impetus for this study was the remarkable clinical response seen in our earlier phase I/II clinical trial: a pancreatic cancer patient with drug resistant tumors who showed progression of disease following three infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) was restarted on the initial low dose of 5-fluorouracil showed complete response, suggesting that BATs infusions may have sensitized patient's tumor for chemoresponsiveness. In the current study, we tested the hypothesis that BATs can sensitize tumors for chemoresponsiveness. Gemcitabine or cisplatin-resistant MiaPaCa-2 and L3.6 cell lines were effectively targeted by EGFR BATs. Priming of drug sensitive or resistant cells with EGFR BATs followed by retargeting with lower concentrations of 50% in...Continue Reading

References

Jan 22, 2003·Advanced Drug Delivery Reviews·Alfred H Schinkel, Johan W Jonker
Oct 25, 2003·Oncogene·Gary D Kruh, Martin G Belinsky
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J WheelerKeith L Black
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Jörg KönigDietrich Keppler
Jun 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John G GribbenLee M Nadler
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott J AntoniaDmitry I Gabrilovich
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip M ArlenWilliam Dahut
Apr 2, 2008·Cancer Science·Hiroaki ItamochiNaoki Terakawa
Jun 27, 2008·Cellular and Molecular Life Sciences : CMLS·H Lage
Oct 23, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Soroosh RadfarHung T Khong
Sep 9, 2010·Neoplasia : an International Journal for Oncology Research·Wolfgang HagmannJohannes Matthias Löhr
Mar 12, 2011·Expert Opinion on Therapeutic Targets·Jiang LongMin Li
Oct 13, 2011·Molecular Cancer·Dagmar BeierChristoph P Beier
May 4, 2016·Oncoimmunology·Archana Thakur, Lawrence G Lum
Jul 30, 2016·Oncology Reviews·Elroy Patrick WeledjiMotaze Sinju
Apr 30, 2017·Oncology Letters·Manu Gnanamony, Christopher S Gondi
Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Dec 2, 2017·International Journal of Molecular Sciences·Marta Prieto-VilaTakahiro Ochiya
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 24, 2018·Stem Cells International·Lan Thi Hanh PhiHyog Young Kwon
May 16, 2018·Frontiers in Cell and Developmental Biology·Rupert Abele, Robert Tampé
Aug 10, 2018·World Journal of Gastroenterology : WJG·Aleksandra Adamska, Marco Falasca
Jan 10, 2019·Proceedings of the National Academy of Sciences of the United States of America·Suping ZhangThomas J Kipps
Mar 3, 2020·Frontiers in Oncology·Reut Hadash-BengadJonatan E Cohen
Apr 17, 2020·Signal Transduction and Targeted Therapy·Liqun YangHongjuan Cui

❮ Previous
Next ❯

Software Mentioned

ImageStream X
Image [UNK]
NovoExpress
FlowJo
GraphPad
Amnis
ImageStream
GraphPad Prism
IDEAS
RTCA

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.